NCT04732598: A Phase III Study of Bevacizumab and Paclitaxel in Combination With Atezolizumab as a Treatment for Locally Advanced Unresectable or Metastatic Hormone Receptor-positive HER2 Negative Breast Cancer

NCT04732598
Breast Cancer Type: HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: 
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 3
Drug Category: Therapeutic Antibody, Tyrosine-Kinase Inhibitor, Immunotherapy, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 20 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: 
Exclusions: Patients with active brain metastases that require treatment; Patients have been treated with investigational Tecentriq/atezolizumab, or other immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4 antibody drugs), or immunostimulants (e.g., interferon, interleukin-2)
https://ClinicalTrials.gov/show/NCT04732598

Comments are closed.

Up ↑